B-Complex: A Nutraceutical SANS Countermeasure
Primary Purpose
Optic Disc Edema, Endothelial Dysfunction
Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Vitamin B-Complex Supplement
Sponsored by
About this trial
This is an interventional prevention trial for Optic Disc Edema
Eligibility Criteria
Inclusion Criteria:
• Must be astronauts selected for 6-12 month missions on the International Space Station
Exclusion Criteria:
• Subjects taking B-vitamin supplements
Sites / Locations
- Johnson Space CenterRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Supplemented with B-Complex
Arm Description
Subjects will take a vitamin B-complex supplement before, during, and after a 6-12 month spaceflight on the International Space Station
Outcomes
Primary Outcome Measures
Optic Disc Edema
Measure change in total retinal thickness during and after flight compared to preflight using OCT
Secondary Outcome Measures
Endothelial function
Assess reactive hyperemia through changes in fingertip temperature
Advanced Glycation End Products (AGE)
Skin autofluorescence (SAF) will be analyzed non-invasively using an AGE reader
Serum folate status
Vitamin status assessed from a fasting blood sample
Red Blood Cell folate status
Vitamin status assessed from a fasting blood sample
Vitamin B6 status
Vitamin status assessed from a fasting blood sample
Vitamin B12 status
Vitamin status assessed from a fasting blood sample
Glucose
Serum glucose from a fasting blood sample
Nitric oxide
Serum nitric oxide from a fasting blood sample
tetrahydrobiopterin
Serum biochemistry from a fasting blood sample
Dihydrobiopterin
Serum biochemistry from a fasting blood sample
Oxidized glutathione
Serum biochemistry from a fasting blood sample
Total antioxidant capacity
Serum biochemistry from a fasting blood sample
Advanced glycation end products
Serum biochemistry from a fasting blood sample
Albumin
Serum biochemistry from a fasting blood sample
Glycated albumin
Serum biochemistry from a fasting blood sample
3-nitrotyrosine
Serum biochemistry from a fasting blood sample
Formate
Serum biochemistry from a fasting blood sample
MMP-2
Serum biochemistry from a fasting blood sample
MMP-9
Serum biochemistry from a fasting blood sample
TIMP-1
Serum biochemistry from a fasting blood sample
TIMP-2
Serum biochemistry from a fasting blood sample
Heparan sulfate
Serum biochemistry from a fasting blood sample
Syndecan-1
Serum biochemistry from a fasting blood sample
Glypican
Serum biochemistry from a fasting blood sample
Hyaluronan
Serum biochemistry from a fasting blood sample
Total lipid peroxides
Serum biochemistry from a fasting blood sample
Full Information
NCT ID
NCT05366933
First Posted
April 29, 2022
Last Updated
September 26, 2022
Sponsor
National Aeronautics and Space Administration (NASA)
Collaborators
Mayo Clinic, Texas A&M University
1. Study Identification
Unique Protocol Identification Number
NCT05366933
Brief Title
B-Complex: A Nutraceutical SANS Countermeasure
Official Title
B-Complex: A Nutraceutical SANS Countermeasure
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2022 (Actual)
Primary Completion Date
July 1, 2027 (Anticipated)
Study Completion Date
September 30, 2028 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Aeronautics and Space Administration (NASA)
Collaborators
Mayo Clinic, Texas A&M University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this project, the investigators propose to test effectiveness of a daily nutraceutical supplement containing bioactive B vitamins to mitigate optic disc edema in astronauts. The proposed countermeasure is intended to maximize functioning of the one-carbon metabolic pathway to provide enough substrate and cofactors to overcome any genetic differences that may impact the efficiency of enzyme function. By optimizing the pathway, this will 1) optimize endothelial function by increasing eNOS coupling and nitric oxide synthesis and 2) optimize collagen firmness and elasticity in the sclera and lamina cribrosa, and 3) minimize changes in total retinal thickness during and after flight.
The protocol includes assessments of ocular health and function, along with determinants of vascular endothelial function, advanced glycation end products, and nutritional status and one carbon biochemistry. These additional measures will be critical for the further definition of the causes of optic disc edema in some astronauts after long-duration space flight, and in understanding the effect of the countermeasure. Finally, the supplemented subjects in this study will be compared against total retinal thickness data from previously flown astronauts known to have not taken supplements during their missions.
Detailed Description
Fasting (8-h) blood samples (7.5 mL SST and 5 mL EDTA tubes, 12.5 mL total per session) will be collected approximately 180 days and 45 days before flight, on approximate flight day 90, and 30 days before landing, Return to Earth +0-2 days and 30 days after landing.
Blood samples will be analyzed for vitamin status and one-carbon biochemistry, as previously described. One blood sample (collected before flight) will be analyzed for approximately 511 SNPs matching the profile of testing from our ongoing research related to optic disc edema. Serum samples will be analyzed for biochemistry measures evaluating endothelial function, vitamin status, and oxidative damage.
Nutritional status assessment data, including inflight dietary intake and body mass data, completed for routine medical requirements will be requested for data sharing. Inflight medical exercise log data as well as available standard measures data will also be requested for data sharing. Medication use/Med Logs will also be requested for data sharing.
Vascular function VENDYS-II (Endothelix, Inc) will be used to assess reactive hyperaemia through changes in fingertip temperature. The test consists of an automated blood pressure measurement followed by cuff occlusion of the right arm for 2 to 5 min. During this time, the fingertip temperature in the right hand decreases because of the lack of circulation in the fingertip. After the cuff is released, blood flow resumes, causing a temperature rebound in the fingertip in a manner that is proportional to vascular reactivity.
Advanced Glycation End (AGE) Products Skin autofluorescence (SAF) will be analyzed non-invasively using an AGE reader (Diagnoptics Technologies, Groningen, the Netherlands). The AGE reader illuminates a skin surface of approximately 4 cm2, guarded against surrounding light, with an excitation light source with wavelength between 300 and 429 nm. This method is based on the fluorescent properties of certain AGEs accumulated in dermal tissue.
OCT and OCT-A Optical coherence tomography (OCT) and OCT-angiography (OCT-A) scans will be acquired using the Spectralis OCT2 (Heidelberg Engineering) before, during, and after flight. The scan pattern includes 24 B-scans centered in a radial pattern over the optic nerve head, as well as a 3.5 mm circle scan surrounding the optic nerve head for assessment of retinal nerve fiber layer thickness and choroid thickness. For OCT-A, five consecutive volume scans will be obtained in these regions, each containing 216 A-scans. These images will be registered, and the consecutive B-scans will be used to calculate the decorrelation among the images to provide split-spectrum amplitude decorrelation angiography (SSADA) images. This decorrelation between consecutive B-scan images will be used to highlight locations where there is blood flow. The density of the perfused peripapillary vessels within the various layers of the retina will be calculated to create a flow density map.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Optic Disc Edema, Endothelial Dysfunction
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Supplemented with B-Complex
Arm Type
Experimental
Arm Description
Subjects will take a vitamin B-complex supplement before, during, and after a 6-12 month spaceflight on the International Space Station
Intervention Type
Drug
Intervention Name(s)
Vitamin B-Complex Supplement
Intervention Description
Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin
Primary Outcome Measure Information:
Title
Optic Disc Edema
Description
Measure change in total retinal thickness during and after flight compared to preflight using OCT
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Endothelial function
Description
Assess reactive hyperemia through changes in fingertip temperature
Time Frame
6 months
Title
Advanced Glycation End Products (AGE)
Description
Skin autofluorescence (SAF) will be analyzed non-invasively using an AGE reader
Time Frame
6 months
Title
Serum folate status
Description
Vitamin status assessed from a fasting blood sample
Time Frame
6 months
Title
Red Blood Cell folate status
Description
Vitamin status assessed from a fasting blood sample
Time Frame
6 months
Title
Vitamin B6 status
Description
Vitamin status assessed from a fasting blood sample
Time Frame
6 months
Title
Vitamin B12 status
Description
Vitamin status assessed from a fasting blood sample
Time Frame
6 months
Title
Glucose
Description
Serum glucose from a fasting blood sample
Time Frame
6 months
Title
Nitric oxide
Description
Serum nitric oxide from a fasting blood sample
Time Frame
6 months
Title
tetrahydrobiopterin
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
Dihydrobiopterin
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
Oxidized glutathione
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
Total antioxidant capacity
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
Advanced glycation end products
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
Albumin
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
Glycated albumin
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
3-nitrotyrosine
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
Formate
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
MMP-2
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
MMP-9
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
TIMP-1
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
TIMP-2
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
Heparan sulfate
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
Syndecan-1
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
Glypican
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
Hyaluronan
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
Title
Total lipid peroxides
Description
Serum biochemistry from a fasting blood sample
Time Frame
6 months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
• Must be astronauts selected for 6-12 month missions on the International Space Station
Exclusion Criteria:
• Subjects taking B-vitamin supplements
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sara Zwart, PhD
Phone
2814833753
Email
sara.zwart-1@nasa.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Eden Fields
Phone
2814837864
Email
eden.e.fields@nasa.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sara R Zwart, PhD
Organizational Affiliation
UTMB
Official's Role
Principal Investigator
Facility Information:
Facility Name
Johnson Space Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77058
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eden Fields
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
31415055
Citation
Zwart SR, Laurie SS, Chen JJ, Macias BR, Lee SMC, Stenger M, Grantham B, Carey K, Young M, Smith SM. Association of Genetics and B Vitamin Status With the Magnitude of Optic Disc Edema During 30-Day Strict Head-Down Tilt Bed Rest. JAMA Ophthalmol. 2019 Oct 1;137(10):1195-1200. doi: 10.1001/jamaophthalmol.2019.3124.
Results Reference
background
PubMed Identifier
28546443
Citation
Zwart SR, Gibson CR, Gregory JF, Mader TH, Stover PJ, Zeisel SH, Smith SM. Astronaut ophthalmic syndrome. FASEB J. 2017 Sep;31(9):3746-3756. doi: 10.1096/fj.201700294. Epub 2017 May 25.
Results Reference
background
PubMed Identifier
30169456
Citation
Smith SM, Zwart SR. Spaceflight-related ocular changes: the potential role of genetics, and the potential of B vitamins as a countermeasure. Curr Opin Clin Nutr Metab Care. 2018 Nov;21(6):481-488. doi: 10.1097/MCO.0000000000000510.
Results Reference
background
PubMed Identifier
34105833
Citation
McGregor HR, Lee JK, Mulder ER, De Dios YE, Beltran NE, Kofman IS, Bloomberg JJ, Mulavara AP, Smith SM, Zwart SR, Seidler RD. Ophthalmic changes in a spaceflight analog are associated with brain functional reorganization. Hum Brain Mapp. 2021 Sep;42(13):4281-4297. doi: 10.1002/hbm.25546. Epub 2021 Jun 9.
Results Reference
background
PubMed Identifier
28611153
Citation
Laurie SS, Vizzeri G, Taibbi G, Ferguson CR, Hu X, Lee SMC, Ploutz-Snyder R, Smith SM, Zwart SR, Stenger MB. Effects of short-term mild hypercapnia during head-down tilt on intracranial pressure and ocular structures in healthy human subjects. Physiol Rep. 2017 Jun;5(11):e13302. doi: 10.14814/phy2.13302.
Results Reference
background
Learn more about this trial
B-Complex: A Nutraceutical SANS Countermeasure
We'll reach out to this number within 24 hrs